X @Wendy O

Company Strategy - Windtree Therapeutics, a publicly listed biotech firm (WINT), plans to raise up to $520 million through equity agreements [1] - The company intends to allocate 99% of the raised funds, approximately $514.8 million, towards acquiring BNB as part of its treasury diversification strategy [1] - Windtree has committed nearly $700 million in total to its treasury diversification strategy [1] Financial Implications - The company's plan is contingent upon shareholder approval to increase authorized shares [2] Partnerships - Windtree has partnered with Kraken to manage its treasury for secure custody and liquidity [2]